Why have we failed to find the low penetrance genetic constituents of common cancers?

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 12, 2002, Pages 1544-1549

  Caporaso, Neil E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLADDER CANCER; BREAST CANCER; BREAST DISEASE; DISEASE ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HEAD AND NECK CANCER; HEREDITY; HUMAN; LUNG CANCER; LUNG DISEASE; NOTE; PHARYNX CANCER; PHENOTYPE; PRIORITY JOURNAL;

FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; LINKAGE (GENETICS); MALE; MUTATION; NEOPLASMS; NEOPLASTIC SYNDROMES, HEREDITARY; PENETRANCE; PHENOTYPE; PREVALENCE; RESEARCH; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY;

EID: 0036912127     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (76)

1. Lander, E., and Schork, N. J. Genetic dissection of complex traits. Science (Wash. DC), 265: 2037-2048, 1994.
2. Risch, N., and Merikangas, K. The future of genetic studies of complex human disease. Science (Wash. DC), 273: 1516-1517, 1996.
3. Hirschhom, J. N., Lohmueller, K., and Hirchhorn, K. A comprehensive review of genetic association studies. Genet. Med., 4: 45-61, 2002.
4. Dunning, A. M., Healey, C. S., Pharoah, P. D., Teare, M. D., Ponder, B. A., and Easton, D. F. A systematic review of genetic polymorphisms is and breast cancer risk. Cancer Epidemiol. Biomark. Prev., 8: 843-854, 1999.
5. Feyler, A., Voho, A., Bouchardy, C., Kuokkanen, K., Dayer, P., Hivonen, A., and Benhamou, S. Myeloperoxidase-G463A polymorphism and lung cancer risk. Cancer Epidemiol. Biomark. Prev., 2002.
6. Xu, L-L., Miller, D. P., Zhou, W., Lynch, T. J., Wain, J. C., Su, L., and Christiana, D. C. The myeloperoxidase-463G
7. Lichtenstein, P., Holm, N. V., Verkasalo, P. K., Iliadou, A., Kaprio, J., Koskenvuo, M., Pukkala, E., Skytthe, A., and Hemminki, K. Environmental and heritable factors in the causation of cancer. N. Engl. J. Med., 78-85, 2000.
8. Risch, N. The genetic epidemiology of cancer: Interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol. Biomark. Prev., 10: 733-734, 2001.
9. Kellermann, G., Shaw, C. R., and Luyten-Kellermann, M. Aryl hydrocarbon hydroxylase inducibility and brochogenic carcinoma. N. Engl. J. Med., 289: 934-937, 1973.
10. Ayesh, R., Idle, J. R., Ritchie, J. C., Crothers, M. J., Hetzel, M. R. Metabolic oxidation phenotypes as markers of susceptibility to lung cancer susceptibility. Nature (Lond.), 312: 169-170, 1984.
11. Seidegard, J., Pero, R. W., Miller, D. G., and Beattie, E. J. A glutathione transferase in human leukocytes as a marker of susceptibility to lung cancer. Carcinogenesis (Lond.), 7: 751-753, 1986.
12. Lower, G. M., Jr., Nilsson, T., Nelson, C. E., Wolf, H., Gamsky, T. E., Bryan, G. T. N-Acetyltransferase phenotype and risk in urinary bladder cancer: approaches in molecular epidemiology. Preliminary results in Sweden and Denmark. Environ. Health Perspect., 29: 71-79, 1979.
13. Hein, D. W., Doll, M. A., Fretland, A. J., Leff, M. A., Webb, S. J., Xiao, G. H., Devanaboyina, V. S., Nangiu, N. A., and Feng, Y. Molecular Genetics and epidemiology of the NATI and NAT2 acetylation polymorphisms. Cancer Epidemiol. Biomark. Prev., 9: 29-42, 2000.
14. Marcus, P. M., Vineis, P., and Rothman, N. NAT2 slow acetylation and bladder cancer risk: A metanalysis of 22 case-control studies conducted in the general population. Pharmacogenetics, 10: 115-122, 2000.
15. Bartsch, H., Nair, U., Risch, A., Rojas, M., Wikman, H., and Alexandrov, K. Genetic polymorphisms of CYP genes, alone or in combination, as a risk modifier of tobacco associated cancer. Cancer Epidemiol. Biomark. Prev., 9: 3-28, 2000.
16. Houlston, R. S. Glutathione S-transferase M1 status and lung cancer risk: A meta-analysis. Cancer Epidemiol. Biomark. Prev., 8: 675-682, 1999.
17. McWilliams, J. E., Sanderson, B. J. S., Harris, E. L., Richert-Boe, K. E., and Henner, W. D. Glutathione S-transferase M1 (GSTMI) deficiency and lung cancer risk. Cancer Epidemiol. Biomark. Prev., 4: 589-594, 1995.
18. Benhamou, S., Lee, W. J., Alexandrie, A. K., Boffetta, P., Bouchardy, C., Butkiewicz, D., Brockmoller, J., Clapper, M. L., Daly, A., Dolzan, V., Ford, J., Gaspari, L., Haugen, A., Hirvonen, A., Husgafvel-Pursiainen, K., Ingelman-Sundberg, M., Kalina, I., Kihara, M., Kremers, P., Le Marchand, L., London, S. J., Nazar-Stewart, V., Onon-Kihara, M., Rannug, A., Romkes, M., Ryberg, D., Seidegard, J., Shields, P., Strange, R. C., Stucker, I., To-Figueras, J., Brennan, P., and Taioli, E. Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis (Lond.), 8: 1343-1350, 2002.
19. Rostami-Hodjegan, A., Lennard, M. S., Woods, H. F., and Tucker, G. T. Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics, 8: 227-238, 1998.
20. Hoover, R. N. Cancer-nature, nurture or both. N. Engl. J. Med. 343: 135-136, 2000.
21. Rothman, N., Wacholder, S., Caporaso, N. E., Garcia-Closas, M., Buetow, K., Fraumeni, J. R., Jr. The use of common genetic polymorphisms to enhance the epidemiologic study of environmental carcinogens. Biochim. Biophys. Acta, 1471: C1-C10, 2001.
22. Caporaso, N., and Goldstein, A. Cancer genes: Single and susceptibility: Exposing the difference. Pharmacogenetics, 5: 59-63, 1995.
23. Weed, D. L., and Gorelic, L. S. The practice of causal inference in cancer epidemiology. Cancer Epidemiol. Biomark. Prev., 5: 303-311, 1996.
24. Bradford-Hill A. Principles of Medical Statistics. 1971. London: Oxford University Press.
25. Mallet, W. G., Mosebrok, D. R., and Trush, M. A. Activation of (+)trans-7, 8-dihydrohenzo(a)pyrene to diolepoxides by human polymorphonuclear leucocytes or myeloperoxidase. Carcinogenesis (Lond.), 12: 251-254, 1991.
26. Hoy, A., Leininger-Muller, B., Kutter, D., Siest, G., and Visvikis, S. Growing significance of myeloperoxidase in non-infectious diseases. Clin. Chem. Lab. Med., 40: 2-8, 2002.
27. Masuda, M., Suzuki, T., et al. Chlorination of guanosine and other nucleosides by hypochlorous acid and myeloperoxidase of activated human neutrophils. J. Biol. Chem. 276: 40486-40496, 2001.
28. London, S. J., Lehan, T. A., and Taylor, J. A. Myeloperoxidase Genetic Polymorphism and lung cancer risk. Cancer Res., 57: 5001-5003, 1997.
29. Le Marchand, L., Seifried, A., Lum, A., and Wilkens, L. R. Association of the myeloperoxidase -463G-
30. Cascorbi, I., Henning, S., Brockmoller, J., et al. Substantially reduced eisk of cancer of the Aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res., 60: 644-649, 2000.
31. Schabath, M. B., Spitz, M. R., Hong, W. K., Delclos, G. L., Reynolds, W. F., Gunn, G. B., Whitehead, L. W., and Wu, X. A myeloperoxidase polymorphism associated with reduced risk of lung cancer. Lung Cancer, 37: 35-40, 2002.
32. Misra, R. R., Tangrea, J. A., Virtamo, J., Ramasinghe, D., Andersen, M. R., Barrett, M., Taylor, P. R., and Albanes, D. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer riskamong male smokers in Finland. Cancer Lett., 164: 161-167, 2001.
33. Kantarci, O. H., Lesnick, T. G., Yang, P., Meyer, R. L., Hebrink, D. D., McMurray, C. T., and Weinshenker, B. G. Myeloperoxidase -463 (G-
34. Cascorbi, I., Henning, S., Brockmoller, J., Gephart, J., Meisel, C., Muller, J. M., Loddenkemper, R., and Roots. I. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant-463A of the myeloperoxidase gene. Cancer Res., 60: 644-649, 2000.
35. Matsuo, K., Hamajima, N., Suzuki, R., Nakamura, S., Seto, M., Morishima, Y., and Tajima, K. No substantial difference in genotype frequencies of interleukin and myeloperoxidase polymorphismsbetween malignant lymphoma patients and non-cancer controls. Haematologica. 86: 602-608, 2001.
36. Reynolds, W. F., Patel, K., Pianko, S., Blatt, L. M., Nicholas, J. J., and McHutchison, J. G. A genotypic association implicates myeloperoxidase in the progression of hepatic fibrosis in chronic hepatitis C virus infection. Genes Immun., 6: 345-349, 2002.
37. Hoy, A., Leininger-Muller, B., Kutter, D., Siest, G., and Visvikis, S. Growing significance of myeloperoxidase in non-infectious diseases. Clin. Chem. Lab. Med., 40: 2-8, 2002.
38. Brockstedt, U., Krajinovic, M., Richer, C., Mathonnet, G., Sinnett, D., Pfau, W., and Labuda D. Analyses of bulky DNA adduct levels in human breast tissue and genetic polymorphisms of cytochromes P450 (CYPs), myeloperoxidase (MPO), quinone oxidoreductase (NQO1), and glutathione S-transferases (GSTs). Mutat. Res., 516: 41-47, 2002.
39. Garcia-Closas, M., Rothman, N., and Lubin, J. Misclassification in casecontrol studies of gene-environment interactions: Assessment of bias and sample size. Cancer Epidemiol. Biomark. Prev., 8: 1043-1050, 1999.
40. Wacholder, S., Rothman, N., and Caporaso, N. Counterpoint: bias from population stratification is not a major threat to the validity of conclusions from epidemiological studies of common polymorphisms and cancer. Cancer Epidemiol. Biomark. Prev., 11: 513-520, 2002.
41. Thompson, J. R. Invited commentary: Re: Multiple comparisons and related issues in the interpretation of epidemiological data. Am. J. Epidemiol. 147: 801-806, 1998.
42. Little, J., Bradley, L., Bray, M. S., Clyne, M., Dorman, J., Ellsworth, D. L., Hanson, J., Khoury, M., Lau, J., O'Brien, T. R., Rothman, N., Stroup, D., Taioli, E., Thomas, D., Vainio, H., Wacholder, S., and Weinberg, C. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am. J. Epidemiol., 156: 300-310, 2002.
43. Wacholder, S., McLaughlin, J., Silverman, D., and Mandel, J. S. Selection of controls in case-control Studies! Principles. Am. J. Epidemiol., 135: 1019-1049, 1992.
44. Morton, N. E., and Collins, A. Tests and estimates of allelic association in complex inheritance. Proc. Natl. Acad. Sci. USA, 95: 11389-11393, 1998.
45. Cardon, L. R., and Bell, J. I. Association study designs for complex disease. Nature Reviews, 2: 91-99, 2001.
46. Sher L. Psychiatric diagnoses and inconsistent results of association studies in behavioral genetics. Med Hypotheses, 54: 207-209, 2000.
47. Chanock, S., and Wacholder, S. One gene and one outcome? No way. Trends Mol. Med., 8: 266-269, 2002.
48. Koopmans, J. R., Slutske, W. S., Heath, A. C., Neale, M. C., and Boomsma, D. I. The genetics of smoking initiation and quantity smoked in Dutch adolescent and young adult twins. Behav. Genet., 29: 383-393, 1999.
49. True, W. R., Xian, H., Scherrer, J. F., Madden, P. A., Bucholz, K. K., Heath, A. C., Eisen, S. A., and Lyons, M. J. Common genetic vulnerability for nicotine and alcohol dependence in men. Arch. Gen. Psychiatry, 56: 655-661, 1999.
50. Tyndale, R. F., and Sellers, E. M. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther. Drug. Monit., 24: 163-171, 2002.
51. Kishi, K., Gurney, J. W., Schroeder, D. R., Scanlon, P. D., Swensen, S. J., and Jett, J. R. The correlation of emphysema or airway obstruction with the risk of lung cancer: A matched case-controlled study. Eur. Respir. J., 19: 1093-1098, 2002.
52. Yang, P., Wentzlaff, K. A., Katzmann, J. A., et al. α1-antitrypsin deficiency allele carriers among lung cancer patients. Cancer Epidemiol. Biomark. Prev., 8: 461-467, 1999.
53. Harrison, D. J., Cantlay, A. M., Rae, F., Lamb, D., and Smith, C. A. Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum. Exp. Toxicol., 16: 356-360, 1997.
54. Takeyabu, K., Yamaguchi, E., Suzuki, I., Nishimura, M., Hizawa, N., and Kamakami, Y. Gene polymorphism for microsomal epoxide hydrolase and susceptibility to emphysema in a Japanese population. Eur. Respir. J., 15: 891-894, 2000.
55. Weber, W. W. The genetics of acetylation. In: The Acetylator Genes and Drug Response, pp. 32-49. Ann Arbor, MI: 1987, Oxford University Press.
56. Fretland, A. J., Leff, M. A., Doll, M. A., and Hein, D. W. Functional characterization of human N-acetyltransferase 2 (NAT2) single nucleotide polymorphisms. Pharmacogenetics, 11: 207-215, 2001.
57. Bertilsson, L., Dahl, M. L., Dalen, P., and Al-Shurbaji, A. Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol., 53: 111-122, 2002.
58. Hosking, L. K., Boyd, P. R., Xu, C. F., Nissum, M., Cantone, K., Purvis, I. J., Khakhar, R., Barnes, M. R., Liberwirth, U., Hagen-Mann, K., Ehm, M. G., and Riley, J. H. Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activity. Pharmacogenomics J., 2: 165-175, 2002.
59. Weiss, K., and Clark, A. G. Linkage disequilibrium and the mapping of complex human traits. Trends Genet., 18: 19-24, 2002.
60. Hoy, A., Tregouet, D., Leininger-Muller, B., Poirier, O., Maurice, M., Sass, C., Siest, G., Tiret, L., and Visvikis, S. Serum myeloperoxidase concentration in a healthy population: Biological variations, familialresemblance and new genetic polymorphisms. Eur. J. Hum. Genet., 9: 780-786, 2001.
61. Shimada, T., Oda, Y., Gillam, E. M., Guengerich, F. P., and Inoue, K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium. Drug Metab. Dispos., 29: 1176-1182, 2001.
62. Weiss K. M. Genetic Variation and Human Disease, p. 177. Cambridge University Press. Cambridge, 1993.
63. Risch, N., and Teng, J. The relative power of family-based and case-control designs for linkage disequilibrium studies of comples human diseases I DNA pooling. Genome Res., 8: 1273-1288, 1998.
64. Uhl, G. R., Liu, Q-R., Hess, W. J., and Naiman, D. Polysubstance abusevulnerability genes: Genes: Genome scans for association using 1004 subjects and 1494 SNPs. Am. J. Hum. Genet., 69: 1290-1300, 2001.
65. Kruglyak, L., and Nickerson, D. A. Variation is the spice of life. Nat. Genet., 27: 234-235, 2001.
66. Boehnke M. A look at linkage disequilibrium. Nat. Genet., 25: 246-247, 2000.
67. Lazarus, R., Klimecki, W., Palmer, L., Kwiatkowski, D., Silverman, E., Brown, A., Martinez, F., and Weiss, S. Single-nucleotide polymorphisms in the interleukin-10 gene: Differences in frequencies, linkage disequilibrium patterns, and haplotypes in three United States ethnic groups. Genomics, 80: 223, 2002.
68. Kimura, S., and Gonzalez, F. J. Applications of genetically manipulated mice in pharmacogenetics and pharmacogenomics. Pharmacology (Basel), 61: 147-153, 2000.
69. Gregory, S. G., et al. A physical map of the mouse genome Nature (Lond.), 418: 743-750, 2002.
70. Davis, R. E., and Staudt, L. M. Molecular diagnosis of lymphoid malignancies by gene expression profiling. Curr. Opin. Hematol. 9: 333-338, 2002.
71. Little, J., Bradley, L., Bray, M. S., Clyne, M., Dorman, J., Ellsworth, D. L., Hanson, J., Khoury, M., Lau, J., O'Brien, T. R., Rothman, N., Stroup, D., Taioli, E., Thomas, D., Vainio, H., Wacholder, S., and Weinberg, C. Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations. Am. J. Epidemiol., 156: 300-310, 2002.
72. Caporaso, N., Rothman, N., and Wacholder, S. L. Case-control studies of common alleles and environmental factors. J. Natl. Cancer Inst. Monogr., 26: 25-30, 1999.
73. Langholtz, B., Rothman, N., Wacholder, S., and Thomas, D. Cohort studies for characterizing measured genes. J. Natl. Cancer Inst. Monogr., 26: 39-42, 1999.
74. Khoury, M. J., and Yang, Q. The future of genetic studies of complex human diseases: An epidemiologic perspective. Epidemiology, 9: 350-354, 1998.
75. Ioannidis, J. A. P. A., Rosenberg, P. S., Goedert, J. J., and O'Brien, T. R. Commentary: Meta-analysis of individual participants data in genetic epidemiology. Am. J. Epidemiol., 156: 204-210, 2002.
76. Shields, P. G. Publication bias is a scientific problem with adverse ethical outcomes: The case for a section for null results. Cancer Epidemiol. Biomark. Prev., 9: 771-772, 2000.